Last reviewed · How we verify
valproate microgranules
Valproate inhibits histone deacetylase and enhances GABAergic neurotransmission, leading to increased GABA levels and neuronal stabilization.
Valproate inhibits histone deacetylase and enhances GABAergic neurotransmission, leading to increased GABA levels and neuronal stabilization. Used for Epilepsy (seizure disorders), Bipolar disorder (acute mania), Migraine prophylaxis.
At a glance
| Generic name | valproate microgranules |
|---|---|
| Sponsor | Sanofi |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | Histone deacetylase; GABA metabolism |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Valproate works through multiple mechanisms: it inhibits histone deacetylase enzymes, which affects gene expression; increases GABA synthesis and decreases GABA catabolism, enhancing inhibitory neurotransmission; and stabilizes neuronal membranes. The microgranule formulation provides modified-release delivery for improved tolerability and dosing convenience.
Approved indications
- Epilepsy (seizure disorders)
- Bipolar disorder (acute mania)
- Migraine prophylaxis
Common side effects
- Tremor
- Weight gain
- Alopecia (hair loss)
- Thrombocytopenia
- Hepatotoxicity
- Pancreatitis
- Nausea/vomiting
- Sedation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- valproate microgranules CI brief — competitive landscape report
- valproate microgranules updates RSS · CI watch RSS
- Sanofi portfolio CI